Debiopharm is a family-owned biopharmaceutical company founded in 1979 by Dr. Rolland-Yves Mauvernay and headquartered in Lausanne (Vaud/Waadt) with activities in drug development and digital health investment.

Research and manufacturing facilities are located in Martigny (Wallis/Valais). The oncology and bacterial infection-focused company identifies high-potential compounds for in-licensing, clinical development, and commercialisation with partners across the globe.

Headed today by Mr. Thierry Mauvernay, innovation plays a central role at Debiopharm. Each year, over 1.2 million patients benefit from the development of the company’s innovative therapies which target high unmet medical needs for cancer patients and those affected by hard-to-treat bacterial infections.

During the COVID-19 crisis, Debiopharm is evaluating its compound library for potential treatment solutions along with leveraging the diagnostics and monitoring know-how of its portfolio companies such as Immunexpress, Biocartis, and Kaiku. This has led to EU approval of the sepsis triage test, SeptiCyte® RAPID, for COVID-19 patients and the use of the remote patient monitoring platform from Kaiku in hospital settings.

The team’s quest to improve patient quality of life through excellence in research & development, drug & delivery system manufacturing, along with digital health solutions has led to the release of 2 standard-of-care cancer therapies, an FDA Breakthrough Therapy Designation in oncology, a series of successful investments in disruptive digital healthcare start-ups such as Kaiku and BC Platforms, and a growing pipeline of 12 specialised medicines that aim to ultimately bring patients closer to a cure. Their ongoing innovation in oncology currently includes antibody drug conjugates, DNA damage repair, pro-apoptotic and anti-tumor immunity enhancing therapies.

Debiopharm has a vision for healthcare that goes well beyond making new medicines available. They endeavour to improve treatment as a whole, from diagnostics to medication and monitoring, in order to impact the lives of patients throughout their overall journey. With over 400 employees in Switzerland, their 40 years of commitment to patients through translational and clinical research while keeping innovation central in all they do, has earned Debiopharm their title as a Swiss Success Story.